[THE SYNDROME «LOW TRIIODOTHYRONINE» AND A COURSE A HEART FAILURE]

S Pyvovar1, Yu Rudyk1, T Lozyk1

  • 1The Government Institution "L.T.Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine", Kharkiv, Ukraine.

Georgian Medical News
|June 20, 2019
PubMed

Insights

Low triiodothyronine syndrome (LT3S) in heart failure (HF) patients with post-infarction cardiosclerosis is linked to younger age and higher re-hospitalization risk. Serum T3f levels below 2.07 pmol/l indicate LT3S.

Area of Science:

  • Cardiology
  • Endocrinology
  • Internal Medicine

Background:

  • Heart failure (HF) is a complex condition often associated with other comorbidities.
  • Post-infarction cardiosclerosis, a consequence of myocardial infarction, can lead to or exacerbate HF.
  • Low triiodothyronine syndrome (LT3S) is observed in various critical illnesses, but its specific impact on HF post-myocardial infarction requires further investigation.

Purpose of the Study:

  • To investigate the effect of low triiodothyronine syndrome (LT3S) on the clinical course of heart failure (HF) in patients with post-infarction cardiosclerosis.
  • To establish diagnostic criteria for LT3S in this patient population.
  • To identify predictors of re-hospitalization in HF patients with LT3S.

Main Methods:

  • A biennial study involving 157 patients hospitalized with HF secondary to coronary heart disease and myocardial infarction.
  • Standardized assessment including hemodynamic parameters, clinical and biochemical blood tests, and thyroid hormone levels (TSH, free T3, free T4, reverse T3).
  • Statistical analysis to determine the diagnostic threshold for LT3S and develop a regression model for re-hospitalization risk.

Main Results:

  • A serum free T3 (fT3) level ≤2.07 pmol/l was identified as a diagnostic marker for LT3S in HF patients with post-infarction cardiosclerosis.
  • The prevalence of LT3S in hospitalized HF patients was 17.8%.
  • Patients with LT3S were younger, exhibited larger left ventricular dimensions, reduced ejection fraction, and a significantly higher relative risk of re-hospitalization within 2 years (2.224 [1.363-3.630]).
  • A regression model for HF re-hospitalization included weight, thyroxine and triiodothyronine concentrations, non-toxic goiter, height, total cholesterol, LDL cholesterol, and blood granulocytes. Risk increased with a model score ≥1.321 (sensitivity 93.78%, specificity 40.45%).

Conclusions:

  • LT3S is a significant finding in HF patients with post-infarction cardiosclerosis, associated with distinct clinical characteristics.
  • Serum fT3 levels serve as a reliable diagnostic indicator for LT3S in this cohort.
  • LT3S is a strong predictor of HF decompensation and re-hospitalization, highlighting the importance of thyroid hormone assessment in managing these patients.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
798
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.1K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
737
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
280
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
830
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
232